Both Seattle and Pieris have been busy on the deal front, and today their lists grew longer as the two pair on developing immuno-oncology treatments.

Syndesi begins life with a $20.9 million infusion, to carry a SV2A modulator through early proof of concept.

Celltex Therapeutics and Texas A&M Institute for Regenerative Medicine hope to have a stem cell-derived therapy for Alzheimer’s within three years.

Chinese biotech NetVation DL Medicine has arrived on the scene with a two-year alliance with Pfizer, plus an equity investment from the big pharma group.

Warp Drive has been working to live up to its name, speeding through development and deals.

After a deal for Immunomedics fell through last May, Seattle Genetics has scaled down spending to ink a $614 million deal for Cascadian Therapeutics.

Vical, hit with trial flop after trial flop—including a cytomegalovirus vaccine licensed from Astellas—is letting go of around half of its workforce.

BridgeBio will develop the drug for FGFR-related diseases, including bile duct cancer and a form of dwarfism.